Schneeweiss S - Search Results

1

Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0.

Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M; joint ISPE-ISPOR Special Task Force on Real World Evidence in Health Care Decision Making. Wang SV, et al. Among authors: schneeweiss s. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1018-1032. doi: 10.1002/pds.4295. Pharmacoepidemiol Drug Saf. 2017. PMID: 28913963 Free PMC article.

2

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Schneeweiss S, et al. N Engl J Med. 2002 Mar 14;346(11):822-9. doi: 10.1056/NEJMsa003087. N Engl J Med. 2002. PMID: 11893794 Free article.

3

Clozapine use and risk of diabetes mellitus.

Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Wang PS, et al. Among authors: schneeweiss s. J Clin Psychopharmacol. 2002 Jun;22(3):236-43. doi: 10.1097/00004714-200206000-00002. J Clin Psychopharmacol. 2002. PMID: 12006892

4

Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance.

Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ. Schneeweiss S, et al. J Clin Epidemiol. 2002 Aug;55(8):833-41. doi: 10.1016/s0895-4356(02)00437-7. J Clin Epidemiol. 2002. PMID: 12384199

5

Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.

Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB. Duetz MS, et al. Among authors: schneeweiss s. Clin Ther. 2003 Jan;25(1):273-84. doi: 10.1016/s0149-2918(03)90037-3. Clin Ther. 2003. PMID: 12637126

6

Improved comorbidity adjustment for predicting mortality in Medicare populations.

Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Schneeweiss S, et al. Health Serv Res. 2003 Aug;38(4):1103-20. doi: 10.1111/1475-6773.00165. Health Serv Res. 2003. PMID: 12968819 Free PMC article.

7

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Schneeweiss S, et al. Clin Pharmacol Ther. 2003 Oct;74(4):388-400. doi: 10.1016/S0009-9236(03)00227-3. Clin Pharmacol Ther. 2003. PMID: 14534526

8

Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?

Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Solomon DH, et al. Among authors: schneeweiss s. Am J Med. 2003 Dec 15;115(9):715-20. doi: 10.1016/j.amjmed.2003.08.025. Am J Med. 2003. PMID: 14693324

9

Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.

Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Schneeweiss S, et al. BMJ. 2004 Mar 6;328(7439):560. doi: 10.1136/bmj.38020.698194.F6. Epub 2004 Feb 24. BMJ. 2004. PMID: 14982865 Free PMC article. Clinical Trial.

10

Use of the case-crossover design to study prolonged drug exposures and insidious outcomes.

Wang PS, Schneeweiss S, Glynn RJ, Mogun H, Avorn J. Wang PS, et al. Among authors: schneeweiss s. Ann Epidemiol. 2004 Apr;14(4):296-303. doi: 10.1016/j.annepidem.2003.09.012. Ann Epidemiol. 2004. PMID: 15066610

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

625 results

Search Page

Filters